

Real-World Outcomes of Adjuvant Pembrolizumab in Renal Cell Carcinoma: A Single-Centre Experience: IUC26628-89

Oghenevwe Okuma , Chizoba Nwankwo , Maria Cortez, Mandy Chipuriro, Gillian Barnes, Kishore Kumar
Affiliation: The James Cook University Hospital.



Background

The KEYNOTE-564 trial demonstrated that adjuvant Pembrolizumab significantly improved disease-free survival (DFS) in patients with intermediate and high-risk renal cell carcinoma (RCC) following nephrectomy.

This study aimed to assess real-world outcomes of adjuvant pembrolizumab and compare them with clinical trial data.

Methods

This was a retrospective, single-centre analysis of patients with RCC treated with adjuvant pembrolizumab following nephrectomy from December 2022 to October 2025, with censoring date of 15th May 2026.

Median follow-up of 23.8 months

Results

N=57; Median age: 63 years (range 39–80); Male: 68.4%; ECOG PS 0: 27.1%, PS 1: 82.1%


At a median follow-up of 23.8 months, median disease-free survival (DFS) was not reached, and 78.7% of patients remained disease-free. Treatment-related toxicity was observed in 64.9% of patients, and grade ≥ 3 adverse events reported in only 14%.

The most common irAEs were hypothyroidism (19.2%), skin rash (17.3%), pneumonitis (11.5%), colitis (7.7%), and adrenal insufficiency (7.7%). 49.1% of patients completed planned course of treatment at the time of analysis. 29.9% discontinued due to toxicity, 12.2% due to disease progression

Conclusion


This study demonstrated comparable efficacy and safety of adjuvant pembrolizumab in routine clinical setting

Leibovich Risk





■ High-risk ■ Intermediate-risk ■ N/A

Most Common Immune-Related Adverse Events (irAEs)



Treatment Outcome



Reference:

Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogierio J, Quinn DI, Powles T; KEYNOTE-564 Investigators. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl J Med. 2021 Aug 19;385(8):683-694. doi: 10.1056/NEJMoa2106391. PMID: 34407342.